Wu Xiao-Xiong, Da Wan-Ming, Li Hong-Hua, Zhao Yu, Wang Quan-Shun, Wang Shu-Hong, Zhu Hai-Yan
Department of Hematology, General Hospital of Chinese PLA, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Jun;13(3):394-6.
In order to evaluate the effects of FLAG regimen in treatment of refractory and relapsed acute myeloid leukemia (AML), 27 patients with refractory or relapsed acute myeloid leukemia (10 refractory AML patients, 17 relapsed AML patients) were treated with FLAG regimen. The results show that the rate of complete remission was 48.2% (13/27), the rate of partial remission was 14.8% (4/27), and the overall response rate was 63.0%. Main toxicities were gastrointestinal side effectes, myelosupression and neutropenia. It is concluded that FLAG regimen can be employed in treatment of the refractory or relapsed patients who were not respond to other regimen, and the regiment was safe.
为评估FLAG方案治疗难治性和复发性急性髓系白血病(AML)的效果,对27例难治性或复发性急性髓系白血病患者(10例难治性AML患者,17例复发性AML患者)采用FLAG方案进行治疗。结果显示,完全缓解率为48.2%(13/27),部分缓解率为14.8%(4/27),总缓解率为63.0%。主要毒性为胃肠道副作用、骨髓抑制和中性粒细胞减少。结论是,FLAG方案可用于治疗对其他方案无反应的难治性或复发性患者,且该方案安全。